Tumor necrosis factor-alpha antagonists twenty years later: What do cochrane reviews tell us?

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2132-2141

  Akobeng, Anthony A ^a   Sandborn, William J ^b,c   Bickston, Stephen J ^d   Chande, Nilesh ^e   Shackelton, Lisa M ^b   Nelson, Sigrid ^b   Feagan, Brian G ^b,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Efficacy; Inflammatory bowel disease; Meta analysis; Safety; Systematic review; TNF antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CANCER RISK; DRUG EFFICACY; DRUG SAFETY; GASTROENTEROLOGIST; HIGH RISK PATIENT; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925664186     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000218     Document Type: Review

References (51)

1. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483.
2. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55(suppl 1):i16.
3. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. 2004;53(suppl 5):V1-16.
4. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
5. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
6. Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011;60:1754-1763.
7. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
8. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
9. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013;4:CD000545.
10. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.
11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
12. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
13. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
14. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653.
15. Ordas I, Mould DR, Feagan BG, et al. An1 monoclonal antibodies in inflammatory bowel disease; pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-646.
16. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
17. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
18. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139.
19. Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919-927.
20. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial (GAIN). Ann Intern Med. 2007;146:829-838.
21. Panaccione R, Sandborn WJ, D'Haens G, et al. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after IFX failure: 1-year follow-up of GAIN trial. Gastroenterology. 2008;134 (suppl 2):A-133.
22. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8:688-695.
23. Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012;61:229-234.
24. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330:1841-1845.
25. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760-765.
26. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73-78.
27. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-1915.
28. Dean KE, Hikaka J, Huakau JT, et al. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol. 2012;27:487-492.
29. Mocciaro F, Renna S, Orlando A, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis. 2012;6: 681-686.
30. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70.
31. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2004; CD003574.
32. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;CD008794.
33. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
34. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREAT registry. Am J Gastroenterol. 2012;107:1409-1422.
35. Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:1100-1110.
36. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: metaanalysis of randomized controlled trials. Am J Gastroenterol. 2013;108: 1268-1276.
37. Parambir SD, Dubinsky M, Siegel CA. Systematic review of serious infection and lymphoma risk with anti-TNF therapy for pediatric IBD. Gastroenterology. 2013;144(suppl 1):S112.
38. Salanti G. Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3: 80-97.
39. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621-1628.
40. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for nonmelanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.
41. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299-1307.
42. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91: 854-862.
43. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology. 2000;119:647-653.
44. Dayharsh GA, Loftus EV Jr, SandbornWJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72-77.
45. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
46. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625.
47. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
48. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
49. Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol. 2010;105:2299-2301.
50. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72:517-524.
51. Moulis G, Sommet A, Béné J, et al. Cancer risk of anti-TNF-a at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One. 2012;7:e48991.